Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
Prostate cancer is a major public health problem in all the developed countries. Increasing numbers of men with nonmetastatic prostate cancer are receiving long-term androgen deprivation therapy (ADT). ADT is associated the loss of bone mineral density and a increased risk of bone fractures. The standard recommendations for male bone health include above all optimizing calcium and vitamin D intake, and exercise. Vitamin D3 is an essential factor in the maintenance of bone health and calcium homeostasis. The main supply of vitamin D3 is obtained through photosynthesis in the skin. The aim of this study was to investigate the influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients. We divided our androgen deprived prostate cancer patients in 2 groups. The first group (A) consists of 224 patients with insolation rate less then 3 h per week. The second group (B) consists of 174 patients with insolation rate greater then 10 h per week. With a questionnaire we determined, that patients from both groups were 70 to 80 years old, body mass index was 25-30 kg/m2, androgen deprivation was 4-6 years and received no vitamin D supplements. In the group A 21.86% suffered pathologic fractures do to osteoporosis. In the group B 10.92% patients suffered from osteoporotic bone fractures. The risk for pathological bone fractures is significantly greater in the group A. In conclusion higher insolation in androgen deprived nonmetastatic prostate cancer patients significantly decreases the osteoporosis progression and the risk of pathologic bone fractures.
Spanjol
Josip
J
Clinic of Urology, University Hospital Rijeka, Rijeka, Croatia. jspanjol@vip.hr
Maricić
Antun
A
Valencić
Maksim
M
Oguić
Romano
R
Krpina
Kristijan
K
Protić
Alen
A
Ivancić
Aldo
A
Bobinac
Mirna
M
Fuckar
Dora
D
Vojniković
Bozidar
B
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005598:Fractures, Spontaneous / Q000139:chemically induced / Q000517:prevention & control*; D006370:Heliotherapy; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D013472:Sunlight; D014807:Vitamin D / Q000096:biosynthesis
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D014807:Vitamin D